Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Status:
Completed
Trial end date:
2018-03-12
Target enrollment:
Participant gender:
Summary
Background:
- Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The
only treatment for NETs is surgery, but most are found when they are too advanced for
surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can
be successful. They want to test if the study drug can be used along with imaging devices to
detect NETs.
Objectives:
- To see how well a new experimental imaging agent, 68Gallium-DOTATATE, detects unknown
primary and metastatic NETs in the gastrointestinal system and pancreas.
Eligibility:
- Adults over 10 years old with a suspected NET or family history of NET.
Design:
- Participants will be screened with a medical history and physical exam, and have a blood
test.
- Participants will undergo three scans. For all of these, a substance is injected into
their body, they lie on a table, and a machine takes images.
- A standard computed tomography (CT) scan of the chest, abdomen, and pelvis.
- An octreotide scintigraphy Single photon emission computed tomography (SPECT)/CT.
- A 68Gallium-DOTATATE positron emission tomography (PET)/CT. The study drug is injected
into a vein, usually in the arm. Low-dose X-rays go through the body. For about 40
minutes a large, donut-shaped device takes images of the body. The entire session takes
90 to 120 minutes.
- Researchers will compare images from the three scans.
- Participants will have 1 follow-up visit each year for 5 years. At this visit, they will
have a medical exam, blood taken, and a CT scan.